Multidisciplinary Attendee Breakdown
Who Should Attend or Sponsor?
Track 1: Advanced Therapeutics Engineering medicines that change the standard of care
What You’ll Explore
- Engineered cell therapies: CAR-T, TCR, TIL and NK
- Off-the-shelf and in vivo cell therapy platforms
- Breaking the solid-tumor barrier with immune engineering
- Next-generation IO, bispecifics, ADCs and targeted therapy
- Resistance biology, predictive biomarkers and adaptive combinations
- CRISPR, base/prime editing and programmable gene control
- RNA editing, splice modulation, ASOs, siRNA and mRNA
- In vivo delivery, vectors, LNPs and tissue targeting
- Manufacturing, evidence and access from N-of-1 to scale
Who You’ll Meet
- CEOs, Founders, CMOs, CSOs & Heads of R&D — biotech, pharma and advanced-therapy leadership
- Oncology, Hematology & Immunology Chairs — clinicians shaping treatment standards
- Heads of Cell Therapy, Gene Therapy & Genetic Medicines — discovery through translation
- SVPs/VPs of Translational Medicine & Biomarkers — patient selection and response strategy
- Clinical Development & Operations Executives — early-phase through pivotal trials
- Heads of CMC, Manufacturing, Quality & Supply Chain — scale-up and commercialization
- Regulatory, Safety & Pharmacovigilance Leaders — approval and lifecycle risk
- Market Access, Reimbursement & Payer Executives — evidence, coverage and patient access
- Business Development, External Innovation, Corporate Strategy & Venture Leaders — partnerships and capital
Best-Fit Sponsors
- Cell, gene, RNA and genome-editing platforms
- Vector, LNP and targeted-delivery technologies
- CDMOs, CROs and clinical-trial networks
- Cell processing, automation and manufacturing systems
- Potency, release, safety and biomarker assays
- Single-cell, spatial and multi-omics technologies
- ADC, antibody and protein-engineering platforms
- GMP, MES, QMS, eBR and regulatory software
- Cold-chain, logistics and patient-support services
- Clinical-stage biotechs seeking partners and investors
Track 2: AI in Precision Medicine AI that ships, scales and discovers
What You’ll Explore
- Multimodal AI across pathology, imaging, genomics and EHR data
- Computational pathology beyond what the human eye can see
- AI-enabled companion diagnostics and patient selection
- Clinical AI agents and decision support in real workflows
- Foundation models for human biology and medicine
- AI-powered clinical trials and regulatory-grade RWE
- Target discovery, protein design and generative chemistry
- Data infrastructure, MLOps and enterprise deployment
- Safety, governance, evaluation and equitable performance
Who You’ll Meet
- CEOs, Chief AI Officers, Chief Digital Officers & Chief Data Officers — health AI and biopharma leadership
- CIOs, CTOs, CMIOs & Chief Analytics Officers — enterprise clinical deployment
- Heads of AI/ML, Data Science & Computational Biology — pharma, diagnostics and health systems
- Radiology, Pathology & Clinical Informatics Chairs — frontline adoption and validation
- SVPs/VPs of Clinical Development, RWE & Trial Innovation — evidence generation
- Product, Engineering, Platform & MLOps Executives — shipping regulated AI at scale
- Heads of Governance, Safety, Privacy & Cybersecurity — trustworthy deployment
- Digital Health Founders & Clinical Product Leaders — workflow and patient solutions
- Corporate Strategy, Business Development, External Innovation & Investors — partnerships and growth
Best-Fit Sponsors
- Cloud, GPU, accelerator and high-performance-compute providers
- EHR, CDS and interoperability platforms
- Imaging, digital-pathology, PACS and edge-device vendors
- FHIR, ETL, data-lake and enterprise analytics platforms
- Model evaluation, governance, monitoring and audit tools
- RWE, HEOR and clinical-trial analytics companies
- Privacy, security, consent and identity providers
- AI drug-discovery and laboratory-automation platforms
- Annotation, curation and synthetic-data providers
- Digital-health and clinical-AI companies ready to scale
Track 3: Precision Diagnostics Detect earlier, treat smarter, monitor continuously
What You’ll Explore
- Risk-stratified screening and the next generation of early detection
- Methylation, fragmentomics, host response and multimodal signals
- MRD as a treatment-decision engine
- Longitudinal monitoring of resistance, response and relapse
- Companion diagnostics for IO, ADCs and cell therapy
- Integrating tissue, liquid, imaging and clinical biomarkers
- ClinOmics in real clinical practice
- Transplant and organ-health monitoring from blood
- Metagenomic diagnostics for infection and the undiagnosed
- Maternal-fetal diagnostics and actionable non-cancer blood tests
Who You’ll Meet
- CEOs, CMOs, CSOs & Heads of Diagnostics — assay and platform-company leadership
- Oncology, Pathology & Laboratory Medicine Chairs — clinical adoption and standards
- Medical & Scientific Directors of CLIA/CAP Laboratories — validation and operations
- SVPs/VPs of Biomarkers, Companion Diagnostics & Translational Medicine — therapy guidance
- Heads of Early Detection, MRD & Disease Monitoring — oncology and beyond
- Clinical Chiefs in Transplant, Infectious Disease & Maternal-Fetal Medicine — emerging blood-based applications
- Bioinformatics, Computational Genomics & Assay Development Executives — signal to interpretation
- Payer, HTA, Market Access & Health Economics Leaders — utility, coverage and reimbursement
- Regulatory, Quality, Pharma Alliance, Corporate Strategy & Diagnostics Investment Leaders — approval and commercialization
Best-Fit Sponsors
- MCED, MRD and liquid-biopsy platforms
- Multi-disease blood-based diagnostic companies
- Methylation, fragmentomics, cfRNA, EV and proteomic technologies
- Short- and long-read sequencing, sample prep and assay chemistry
- AI diagnostics, interpretation and decision-support software
- Reference laboratories and CLIA testing services
- CDx co-development and clinical-trial assay partners
- Biobanking, pre-analytics, automation and cold-chain providers
- Standards, quality and proficiency-testing organizations
- Market-access, reimbursement and regulatory advisors
Track 4: Genomic Medicine, Implementation & Longevity From sequence to system-wide precision care
What You’ll Explore
- Rare-disease diagnosis beyond the exome
- Newborn sequencing and population genomic screening
- Structural variants, long reads and closing the diagnostic gap
- Moving from genomic diagnosis to targeted treatment
- Precision-medicine operating models that actually work
- EHR integration and decision support clinicians will use
- Coverage, evidence and value-based implementation
- Community access, equity and population-scale delivery
- Aging biology, GLP-1 and prevention
- Biomarkers, wearables and clinical trials for healthspan
Who You’ll Meet
- Health-System CEOs, CMOs, CSOs, CIOs & Chief Strategy Officers — enterprise precision care
- Heads of Genomic Medicine, Rare Disease & Molecular Diagnostics — sequence to action
- Genetics, Pediatrics & Laboratory Medicine Chairs — newborn and rare-disease programs
- SVPs/VPs of Precision Medicine, Population Health & Clinical Transformation — system-wide implementation
- Heads of Bioinformatics, Data Architecture, LIS/LIMS & Interoperability — the operating backbone
- Payer, Value-Based Care, Quality & Evidence Executives — coverage and outcomes
- Heads of Clinical Decision Support, Digital Health & Innovation — workflow adoption
- Geroscience, Metabolic Health & Longevity Institute Leaders — prevention and healthspan
- Business Development, Corporate Strategy, External Innovation & Investors — scaling new models
Best-Fit Sponsors
- WGS, WES, long-read and newborn-screening partners
- Variant interpretation, curation and knowledgebase platforms
- EHR, interoperability and clinical-decision-support vendors
- Cloud data, analytics, governance and integration platforms
- LIS, LIMS, metadata, lineage and workflow systems
- Biobank, registry and sample-management companies
- Payers and value-based-care partners
- Implementation and change-management consultancies
- Aging biomarkers, wearables and digital-endpoint companies
- Prevention, metabolic-health and longevity innovators
Track 5: Precision Frontiers Map tissue, reset immunity, decode the brain
What You’ll Explore
- Spatial transcriptomics, proteomics and tissue architecture
- Human cell atlases and cell-state-driven target discovery
- Spatial pathology, foundation models and clinical biomarkers
- Scaling spatial technologies from discovery to diagnostics
- Immune reset and CAR-T approaches in autoimmune disease
- Tolerance, Tregs and durable disease modification
- Immune signatures, patient stratification and smarter trials
- Blood biomarkers for Alzheimer’s and neurodegeneration
- Precision diagnosis across stroke, epilepsy, Parkinson’s, ALS and FTD
- AI neuroimaging, digital biomarkers and circuit-based therapies
Who You’ll Meet
- CEOs, CMOs, CSOs & Heads of R&D — spatial biology, immunology and neuroscience companies
- Heads of Spatial Biology, Single-Cell Science & Tissue Profiling — atlas to application
- Pathology, Immunology, Rheumatology, Neurology & Neuroscience Chairs — cross-disease clinical leadership
- SVPs/VPs of Translational Medicine, Biomarkers & Precision Research — patient stratification
- Heads of Autoimmune, Neurodegeneration & Brain Health Programs — emerging treatment categories
- Clinical Development, Trial Strategy & Medical Affairs Executives — proof to practice
- Imaging, Digital Biomarker, AI & Computational Biology Leaders — multimodal precision phenotyping
- Business Development, External Innovation & Corporate Strategy Executives — scientific and commercial partnerships
- Venture, Growth & Strategic Investors — building the next precision frontier
Best-Fit Sponsors
- Spatial transcriptomics, proteomics and imaging platforms
- Single-cell, tissue-analysis and digital-pathology technologies
- AI foundation-model and spatial-informatics companies
- Autoimmune and inflammatory-disease biopharma
- Immune-reset, tolerance, Treg and cell-therapy platforms
- Neurodiagnostic, blood-biomarker and reference-lab companies
- Neuroimaging AI, EEG, wearable and digital-biomarker platforms
- Neurology CROs, imaging cores and trial-technology providers
- Biobanks, tissue networks and translational-service partners
- Clinical-stage companies seeking scientific and commercial partners
Colleague Feedback — PMWC
“
You have truly created something of a “Davos of personalized medicine” conference, which has value beyond ASCO and ASH.
PMWC is indeed 'The Davos of Biotech'
There is no other event with such a lineup of leaders in their field. My annual MUST event since 2013!
Now THAT is a stellar line up!!
I am thrilled to hear about the impressive lineup of speakers and the engaging topics planned for the conference.
PMWC is a landmark event, a real tour de force in precision medicine!
Congrats. This is an amazing rock star lineup.
The PMWC program and speaker lineup is one of the most impactful and thoughtfully curated conferences in healthcare today.
I’ve spoken and had exhibitions in the past at PMWC — one of my favorite conferences of the year — and this lineup is extra impressive.
Tal has done an amazing job developing the PMWC into the #1 premier precision medicine conference.
Incredible line up! Great event you are putting on
What an impressive lineup.
Congratulations on the amazing speaker lineup. Wow!
PMWC was excellent, and the lineup sounds truly impressive!
The line up has come together beautifully and quite impressively. Many people have mentioned how much they are looking forward to it.
